Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C
Front Immunol. 2025; 16:1519866.
PMID: 39958330
PMC: 11827429.
DOI: 10.3389/fimmu.2025.1519866.
Anter J, Yakimovich A
Methods Mol Biol. 2025; 2890:291-333.
PMID: 39890733
DOI: 10.1007/978-1-0716-4326-6_15.
Rathnasinghe R, Chang L, Pearl R, Jangra S, Aspelund A, Hoag A
NPJ Vaccines. 2024; 9(1):169.
PMID: 39300090
PMC: 11413010.
DOI: 10.1038/s41541-024-00952-7.
Lau Y, Shan S, Wang D, Chen D, Du Z, Lau E
PLoS Comput Biol. 2024; 20(7):e1012311.
PMID: 39083536
PMC: 11318919.
DOI: 10.1371/journal.pcbi.1012311.
Li Y, Liang G, Chen Z, Zhang K, Liang J, Jiang L
Acta Pharmacol Sin. 2024; 45(11):2380-2393.
PMID: 38987389
PMC: 11489770.
DOI: 10.1038/s41401-024-01331-7.
H3N2 canine influenza virus-like particle vaccine with great protection in beagle dogs.
Ge F, Shen L, Yang D, Yang X, Li X, Shen H
Microbiol Spectr. 2024; :e0044524.
PMID: 38874403
PMC: 11323971.
DOI: 10.1128/spectrum.00445-24.
Influenza Virus Inactivated by Heavy Ion Beam Irradiation Stimulates Antigen-Specific Immune Responses.
Schulze K, Weber U, Schuy C, Durante M, Guzman C
Pharmaceutics. 2024; 16(4).
PMID: 38675126
PMC: 11054185.
DOI: 10.3390/pharmaceutics16040465.
Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2.
Li R, Chang Z, Liu H, Wang Y, Li M, Chen Y
J Nanobiotechnology. 2024; 22(1):44.
PMID: 38291444
PMC: 10825999.
DOI: 10.1186/s12951-024-02293-y.
A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.
Chumbe A, Grobben M, Capella-Pujol J, Koekkoek S, Zon I, Slamanig S
Virus Res. 2024; 341:199308.
PMID: 38171391
PMC: 10821612.
DOI: 10.1016/j.virusres.2024.199308.
One HA stalk topping multiple heads as a novel influenza vaccine.
Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C
Emerg Microbes Infect. 2023; 13(1):2290838.
PMID: 38044872
PMC: 10810646.
DOI: 10.1080/22221751.2023.2290838.
Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine.
Gomes K, Zhang Y, Lee Y, Eldad M, Lim A, Ward G
ACS Nano. 2023; 17(23):23545-23567.
PMID: 37988765
PMC: 10722606.
DOI: 10.1021/acsnano.3c06526.
Molecular Mechanisms behind Conformational Transitions of the Influenza Virus Hemagglutinin Membrane Anchor.
Michalski M, Setny P
J Phys Chem B. 2023; 127(44):9450-9460.
PMID: 37877534
PMC: 10641832.
DOI: 10.1021/acs.jpcb.3c05257.
Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination.
Bhatnagar N, Kim K, Subbiah J, Muhammad-Worsham S, Park B, Liu R
Vaccines (Basel). 2023; 11(7).
PMID: 37515025
PMC: 10386405.
DOI: 10.3390/vaccines11071209.
Immunopathogenesis of viral infections in neurological autoimmune disease.
Habibi M, Nezhad Shamohammadi F, Rajaei T, Namdari H, Pashaei M, Farajifard H
BMC Neurol. 2023; 23(1):201.
PMID: 37221459
PMC: 10203689.
DOI: 10.1186/s12883-023-03239-x.
Induction of Homosubtypic and Heterosubtypic Immunity to Influenza Viruses Using a Conserved Internal and External Proteins.
Maleki M, Hosseini S, Farahmand B, Saleh M, Shokouhi H, Torabi A
Curr Microbiol. 2023; 80(6):212.
PMID: 37191741
DOI: 10.1007/s00284-023-03331-y.
Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.
Sanchez M, Ebensen T, Schulze K, Cargnelutti D, Scodeller E, Guzman C
Pharmaceutics. 2023; 15(3).
PMID: 36986773
PMC: 10057018.
DOI: 10.3390/pharmaceutics15030912.
Recent Advances in PROTAC-Based Antiviral Strategies.
Ahmad H, Zia B, Husain H, Husain A
Vaccines (Basel). 2023; 11(2).
PMID: 36851148
PMC: 9958553.
DOI: 10.3390/vaccines11020270.
SARS-CoV-2 epitopes inform future vaccination strategies.
Shafqat A, Omer M, Ahmad O, Niaz M, Abdulkader H, Shafqat S
Front Immunol. 2022; 13:1041185.
PMID: 36505475
PMC: 9732895.
DOI: 10.3389/fimmu.2022.1041185.
Influenza Vaccine: An Engineering Vision from Virological Importance to Production.
Demirden S, Alptekin K, Kimiz-Gebologlu I, Oncel S
Biotechnol Bioprocess Eng. 2022; 27(5):714-738.
PMID: 36313971
PMC: 9589582.
DOI: 10.1007/s12257-022-0115-8.
Controlled Human Infection Models To Accelerate Vaccine Development.
Choy R, Louis Bourgeois A, Ockenhouse C, Walker R, Sheets R, Flores J
Clin Microbiol Rev. 2022; 35(3):e0000821.
PMID: 35862754
PMC: 9491212.
DOI: 10.1128/cmr.00008-21.